Global Hepatitis B Human Immunoglobulin Market Insights, Size, and Forecast By Distribution Channel (Direct Sales, Retail Pharmacies, Online Pharmacies), By Application (Prophylaxis for Hepatitis B Virus Exposure, Post-Exposure Prophylaxis for Infants, Prevention of Hepatitis B Infection in At-Risk Populations), By End Use (Hospitals, Clinics, Home Care Settings), By Product Type (Hepatitis B Immunoglobulin, Hepatitis B Vaccine, Combination Therapies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global Hepatitis B Human Immunoglobulin Market is projected to grow from USD 2.8 Billion in 2025 to USD 5.1 Billion by 2035, reflecting a compound annual growth rate of 6.4% from 2026 through 2035. This market encompasses the production, distribution, and sale of human immunoglobulin preparations specifically formulated to provide passive immunity against the Hepatitis B virus. These preparations are derived from the plasma of donors with high levels of Hepatitis B surface antibody and are crucial for post exposure prophylaxis, prevention of mother to child transmission, and prevention of re infection in liver transplant recipients. Key market drivers include the rising global incidence of Hepatitis B infections, increasing awareness regarding the importance of timely prophylaxis, and a growing number of liver transplantation procedures worldwide. Technological advancements in plasma fractionation and purification techniques are also contributing to market expansion by improving product safety and efficacy. However, high treatment costs, stringent regulatory approval processes, and the availability of alternative antiviral therapies pose significant market restraints.
Global Hepatitis B Human Immunoglobulin Market Value (USD Billion) Analysis, 2025-2035
2025 - 2035
www.makdatainsights.com
Important trends shaping the market include the shift towards more targeted and higher purity immunoglobulin products, the emergence of novel delivery methods, and an increasing focus on developing therapeutic applications beyond traditional prophylaxis. The market also observes a growing emphasis on strategic collaborations and partnerships among key players to expand geographic reach and enhance research and development capabilities. Opportunities lie in expanding access to these vital treatments in underserved regions, developing more cost effective manufacturing processes, and exploring potential applications in combination therapies. The market is segmented by product type, application, end use, and distribution channel, with Hospitals emerging as the leading end user segment due to the critical role they play in administering these specialized treatments for both prophylactic and therapeutic purposes.
North America stands out as the dominant region in the global Hepatitis B Human Immunoglobulin Market, driven by a well established healthcare infrastructure, high awareness of Hepatitis B prevention, advanced treatment facilities, and favorable reimbursement policies. Conversely, Asia Pacific is anticipated to be the fastest growing region, fueled by a large patient pool, improving healthcare access, increasing healthcare expenditure, and a rising prevalence of Hepatitis B infections in several countries within the region. Key players such as LFB, Takeda, AbbVie, Kedrion, Sangamo Therapeutics, Biotest, Hemocue, Mitsubishi Tanabe Pharma, Octapharma, and CSL Behring are actively pursuing strategies like product innovation, geographical expansion, and mergers and acquisitions to strengthen their market position and capitalize on emerging opportunities. These companies are investing in R&D to enhance product portfolios and improve manufacturing efficiencies, aiming to meet the evolving demands of the global healthcare landscape.
Quick Stats
Market Size (2025):
USD 2.8 BillionProjected Market Size (2035):
USD 5.1 BillionLeading Segment:
Hospitals (62.4% Share)Dominant Region (2025):
North America (38.2% Share)CAGR (2026-2035):
6.4%
What is Hepatitis B Human Immunoglobulin?
Hepatitis B Human Immunoglobulin is a preparation of antibodies harvested from human plasma. These specific antibodies target the Hepatitis B surface antigen, offering passive immunization. It provides immediate, short-term protection against the Hepatitis B virus by neutralizing free virus particles and infected cells. This is particularly crucial for individuals exposed to Hepatitis B, such as healthcare workers with needlestick injuries, newborns of HBsAg-positive mothers, and those undergoing liver transplants. It bridges the gap before active immunity develops from vaccination or offers protection when active immunity is compromised or insufficient. Its administration is a critical component of post-exposure prophylaxis, significantly reducing the risk of HBV infection.
What are the Trends in Global Hepatitis B Human Immunoglobulin Market
Shifting Focus Prophylaxis to Therapeutic Applications
Rise of Personalized Medicine in HBV Immunoglobulin
Expanding Access Low and Middle Income Nations
Technological Advancements Immunoglobulin Production and Delivery
Shifting Focus Prophylaxis to Therapeutic Applications
Hepatitis B Human Immunoglobulin is increasingly used for therapeutic purposes, such as preventing reinfection in liver transplant patients or managing chronic HBV. Historically, its primary role was post exposure prophylaxis. This reflects a broader shift towards utilizing immunoglobulin for sustained disease management and preventing complications in existing HBV patients, moving beyond its traditional pre exposure and immediate post exposure applications.
Rise of Personalized Medicine in HBV Immunoglobulin
Personalized medicine is emerging in HBV immunoglobulin. Treatment focuses on tailoring therapies to individual patient needs, potentially involving specific antibody profiles or patient derived antibodies. This approach optimizes passive immunization by ensuring the most effective and targeted immunoglobulin is administered, improving therapeutic outcomes for hepatitis B patients globally. This customization refines traditional human immunoglobulin usage.
Expanding Access Low and Middle Income Nations
Expanding access signifies growing availability and affordability of Hepatitis B Human Immunoglobulin in low and middle income countries. This trend reflects increasing awareness of preventative care and the rising prevalence of Hepatitis B in these regions. Efforts by international organizations and pharmaceutical companies are crucial in making this essential treatment more accessible to underserved populations, improving public health outcomes and reducing disease burden in these nations.
Technological Advancements Immunoglobulin Production and Delivery
Technological advancements are revolutionizing immunoglobulin production and delivery for hepatitis B. Innovations in recombinant DNA technology are enabling more efficient and scalable manufacturing processes, potentially lowering costs and increasing supply. Concurrently, new drug delivery systems like subcutaneous injections and targeted therapies are emerging. These advancements promise improved patient convenience, reduced healthcare burden, and enhanced therapeutic outcomes, driving market expansion and accessibility.
What are the Key Drivers Shaping the Global Hepatitis B Human Immunoglobulin Market
Rising Prevalence of Hepatitis B and Liver Diseases
Advancements in Diagnostic Techniques and Early Detection
Increasing Awareness and Prophylactic Immunization Programs
Growing Investment in Research and Development for Novel Therapies
Rising Prevalence of Hepatitis B and Liver Diseases
The increasing incidence of hepatitis B infections globally drives demand for human immunoglobulin. As more people are diagnosed with hepatitis B and related liver conditions such as cirrhosis or liver cancer, the need for prophylactic and therapeutic treatments, including immunoglobulin, escalates. This widespread health challenge fuels market expansion for these vital biologics.
Advancements in Diagnostic Techniques and Early Detection
Improved diagnostic tools like nucleic acid testing and enhanced serological assays enable earlier and more accurate hepatitis B detection. This leads to prompt diagnosis, increasing the need for human immunoglobulin treatment to prevent disease progression, especially in newborns and those exposed to the virus. These advancements fuel the market growth.
Increasing Awareness and Prophylactic Immunization Programs
Growing public knowledge about Hepatitis B and the effectiveness of preventative immunization initiatives is a key driver. These programs actively educate communities on disease transmission, symptoms, and the crucial role of human immunoglobulin in post exposure prophylaxis. This increased understanding naturally fuels demand for this specialized treatment as more individuals seek immediate protection after potential exposure.
Growing Investment in Research and Development for Novel Therapies
Increasing financial commitments by pharmaceutical companies and governments towards discovering and developing innovative therapies for Hepatitis B drives demand for human immunoglobulin. This includes funding for preclinical studies and clinical trials for new drugs and treatments, which often utilize existing immunoglobulin products as part of combination therapies or as a benchmark, thereby expanding market opportunities and product applications globally.
Global Hepatitis B Human Immunoglobulin Market Restraints
Stringent Regulatory Approval Processes for Biologics Impeding Market Entry
Biologics face demanding clinical trials and extensive documentation for regulatory approval. This stringent scrutiny, particularly for novel treatments like hepatitis B immunoglobulin, prolongs development timelines and escalates costs. The complex review process and high bar for demonstrating safety and efficacy significantly delay product launch, impeding timely market entry and patient access to these crucial therapies.
High Cost of Human Immunoglobulin Therapies Limiting Patient Access and Affordability
High costs of human immunoglobulin therapies create a significant barrier for patients requiring treatment for Hepatitis B. These prohibitive expenses directly restrict access, making vital medication unaffordable for many, even where treatment is available. This financial burden severely limits the number of individuals who can practically benefit from these essential therapies globally.
Global Hepatitis B Human Immunoglobulin Market Opportunities
Expanding Geographic Penetration in High-Prevalence Emerging Markets for HBIG
Expanding into high prevalence emerging markets, particularly in Asia Pacific, represents a key opportunity for Hepatitis B Human Immunoglobulin HBIG manufacturers. These regions often have large populations with a significant burden of Hepatitis B, creating substantial unmet medical needs. Penetrating these underserved geographic areas allows companies to address demand for prophylaxis, including preventing mother to child transmission, and managing existing cases. This strategic expansion leverages developing healthcare infrastructures and rising health awareness, promising robust growth by delivering vital public health solutions and improving patient outcomes in these critical markets.
Driving HBIG Adoption through Enhanced Perinatal Screening and Broader Prophylactic Guidelines
Enhanced perinatal screening identifies more Hepatitis B positive mothers, significantly increasing the pool of infants needing prophylaxis. Broader prophylactic guidelines then recommend HBIG for a wider range of these at-risk newborns, extending beyond current strict criteria. This dual strategy substantially expands the addressable market for HBIG, driving its adoption globally. Focusing on robust screening programs and updated guidelines creates a significant opportunity to increase HBIG utilization, particularly in high prevalence regions, ensuring better infant protection and strong market growth.
Global Hepatitis B Human Immunoglobulin Market Segmentation Analysis
Key Market Segments
By Product Type
- •Hepatitis B Immunoglobulin
- •Hepatitis B Vaccine
- •Combination Therapies
By Application
- •Prophylaxis for Hepatitis B Virus Exposure
- •Post-Exposure Prophylaxis for Infants
- •Prevention of Hepatitis B Infection in At-Risk Populations
By End Use
- •Hospitals
- •Clinics
- •Home Care Settings
By Distribution Channel
- •Direct Sales
- •Retail Pharmacies
- •Online Pharmacies
Segment Share By Product Type
Share, By Product Type, 2025 (%)
- Hepatitis B Vaccine
- Combination Therapies
- Hepatitis B Immunoglobulin
www.makdatainsights.com
Why is the Hospitals segment dominating the Global Hepatitis B Human Immunoglobulin Market?
Hospitals represent the leading end use segment due to their central role in critical care and immediate medical interventions. They are equipped with the infrastructure and specialist personnel required for administering immunoglobulin in scenarios like post exposure prophylaxis for infants born to infected mothers, accidental needlestick injuries in healthcare workers, or during liver transplants to prevent reinfection. The comprehensive diagnostic and treatment capabilities available in hospitals ensure precise and timely application, solidifying their substantial market share.
Which application segment is crucial for driving demand in the Global Hepatitis B Human Immunoglobulin Market?
Prophylaxis for Hepatitis B Virus exposure is a pivotal application segment. Human immunoglobulin provides immediate, passive immunity, crucial in situations where rapid protection is needed, such as accidental exposure to infected blood or bodily fluids. This immediate protective effect, especially when active vaccination may not be effective quickly enough or is contraindicated, makes it indispensable for preventing infection in vulnerable individuals, thereby fueling significant market demand.
How do product type and distribution channels influence the Global Hepatitis B Human Immunoglobulin Market?
The Hepatitis B Immunoglobulin product type is central to the market, distinct from vaccines or combination therapies, by offering immediate, passive immunity. This critical distinction drives its demand. Regarding distribution, direct sales often prevail, especially for hospitals, ensuring timely supply of these specialized biological products directly from manufacturers or authorized distributors. Retail and online pharmacies may play a more limited role given the acute administration requirements for most immunoglobulin applications.
What Regulatory and Policy Factors Shape the Global Hepatitis B Human Immunoglobulin Market
Global Hepatitis B Human Immunoglobulin market operates under stringent regulatory oversight given its plasma derived origin. Health authorities worldwide, including FDA and EMA, impose rigorous standards for donor screening, viral inactivation methods, and manufacturing quality GMP. Product approval processes are complex, necessitating extensive clinical data demonstrating safety and efficacy. Pricing and reimbursement policies vary significantly across nations, impacting market access and affordability. Many countries prioritize access through national health systems or subsidies. Regulatory frameworks also mandate comprehensive pharmacovigilance and post market surveillance. While efforts toward global harmonization exist, national specific requirements frequently create market entry barriers. The environment emphasizes product integrity, ethical sourcing, and patient safety paramount.
What New Technologies are Shaping Global Hepatitis B Human Immunoglobulin Market?
Innovations in the Global Hepatitis B Human Immunoglobulin Market focus on enhanced purity and patient convenience. Advanced viral inactivation and nanofiltration techniques are improving product safety and reducing risk. Emerging technologies explore recombinant HBIG alternatives, promising more consistent supply independent of plasma donation and potentially higher potency. Research into subcutaneous formulations aims to revolutionize administration, moving away from solely intravenous delivery for better patient adherence and reduced healthcare burden. Continuous improvements in purification processes and manufacturing efficiency are also driving market evolution, ensuring a more accessible and effective treatment for Hepatitis B prevention post exposure and post transplant recurrence.
Global Hepatitis B Human Immunoglobulin Market Regional Analysis
Global Hepatitis B Human Immunoglobulin Market
Trends, by Region
North America Market
Revenue Share, 2025
www.makdatainsights.com
North America, holding a commanding 38.2% market share, dominates the Global Hepatitis B Human Immunoglobulin market. This regional stronghold is driven by advanced healthcare infrastructure, high diagnosis rates for Hepatitis B, and robust access to specialized treatments. Significant investment in research and development, coupled with favorable reimbursement policies, further solidifies its leading position. The presence of key market players and a concentrated patient pool requiring immunoglobulin therapy also contribute to North America's substantial market influence and continued growth within this vital therapeutic area.
Europe holds a significant share in the Hepatitis B Human Immunoglobulin market due to high healthcare spending and robust regulatory frameworks. Western Europe, particularly Germany, France, and the UK, dominate with advanced medical infrastructure and high awareness of prophylactic treatments for HBV. Eastern European countries are experiencing steady growth, driven by improving healthcare accessibility and rising prevalence of liver diseases. The region also benefits from a strong presence of key pharmaceutical manufacturers and ongoing research in immunotherapies, ensuring a consistent supply and demand for these crucial biologics. Growth is further fueled by increasing adoption of passive immunization for at-risk populations and newborns.
The Asia Pacific region is a critical market for Hepatitis B Human Immunoglobulin, demonstrating the fastest growth globally at a 9.2% CAGR. This surge is driven by a high prevalence of Hepatitis B in countries like China, Indonesia, and Vietnam, coupled with expanding healthcare infrastructure and rising awareness about early diagnosis and treatment. Increased healthcare expenditure and government initiatives promoting vaccination and HBV screening further fuel market expansion. Local manufacturers are also emerging, contributing to increased product availability and affordability, making the region a significant growth engine for the global market.
Latin America’s hepatitis B human immunoglobulin market exhibits varied regional dynamics. Brazil leads due to robust healthcare infrastructure and high incidence. Mexico follows, driven by increasing awareness and improving diagnostic capabilities. Argentina shows steady growth, influenced by government initiatives and rising healthcare expenditure. Other nations like Chile and Colombia demonstrate emerging potential, experiencing increasing demand due to better disease surveillance and improved access to treatment. Market expansion across the region is propelled by a rising birth rate, greater focus on preventing vertical transmission, and increasing prevalence of chronic hepatitis B, leading to growing demand for effective immunoprophylaxis.
MEA's hepatitis B immunoglobulin market is dynamic, driven by high HBV prevalence and improving healthcare infrastructure. Gulf nations lead in per capita spending due to well-funded healthcare systems and increasing awareness campaigns. South Africa and Nigeria are emerging markets, fueled by large populations and growing access to diagnostics and treatment, though affordability remains a barrier. North Africa shows steady growth. Challenges include political instability in certain regions and varying regulatory landscapes impacting market penetration. Overall, the region presents significant growth opportunities due to unmet medical needs and increasing investment in healthcare, particularly for infectious diseases like hepatitis B.
Top Countries Overview
The United States significantly influences the global Hepatitis B Human Immunoglobulin market due to its advanced healthcare infrastructure and pharmaceutical industry. High prevalence of liver diseases and increasing awareness drive demand for hyperimmune globulin. Research and development efforts, coupled with the presence of major manufacturers, ensure a robust supply chain contributing to market growth and accessibility.
China's expanding hepatitis B incidence and large patient pool make it a crucial market for human immunoglobulin. Domestic manufacturers are increasing production, while foreign companies face regulatory hurdles but eye long-term growth. The market sees rising demand for prophylaxis and treatment, influencing global supply and innovation.
India is a growing market for Global Hepatitis B Human Immunoglobulin. Rising prevalence and increased healthcare spending drive demand. Domestic production and imports cater to the need, with a focus on affordability and accessibility, positioning India as a key regional player.
Impact of Geopolitical and Macroeconomic Factors
Geopolitical tensions in key manufacturing regions and supply chain disruptions due to regional conflicts or trade disputes impact production and distribution of hepatitis B immunoglobulin. Furthermore, regulatory changes in major markets like the US or EU, including faster approval pathways or increased post market surveillance, influence market access and competitive dynamics.
Macroeconomic factors such as inflation, currency fluctuations, and interest rate changes directly affect manufacturing costs and the affordability of these treatments. Healthcare spending priorities and budget constraints within national healthcare systems, driven by broader economic conditions, significantly determine market access and reimbursement policies.
Recent Developments
- March 2025
Octapharma announced the launch of a new, high-concentration formulation of its Hepatitis B Immunoglobulin product in key European markets. This formulation aims to reduce infusion volume and improve patient convenience, potentially expanding its market share among existing users.
- January 2025
LFB and Kedrion initiated a strategic partnership focused on optimizing plasma collection and fractionation processes to enhance the global supply of immunoglobulins, including HBIG. This collaboration seeks to improve manufacturing efficiency and ensure a more stable supply chain for critical plasma-derived therapies.
- November 2024
CSL Behring received expanded regulatory approval in several Asian countries for its Hepatitis B Immunoglobulin indication, specifically for post-exposure prophylaxis in certain high-risk populations. This expansion allows CSL Behring to penetrate previously underserved markets and strengthen its regional presence.
- September 2024
Takeda announced a strategic initiative to invest significantly in advanced manufacturing technologies for its immunoglobulin product portfolio, including HBIG. This investment aims to increase production capacity and ensure long-term supply stability in response to growing global demand.
- July 2024
Biotest completed the acquisition of a smaller, specialized plasma collection center network in North America, strengthening its raw material supply chain for immunoglobulin production. This acquisition is expected to improve Biotest's ability to meet increasing demand for its Hepatitis B Immunoglobulin product.
Key Players Analysis
Key players in the Global Hepatitis B Human Immunoglobulin Market like CSL Behring, Octapharma, Kedrion, and Takeda dominate with established plasma fractionation capabilities, ensuring a steady supply of HBIG. LFB also holds a significant position. AbbVie and Mitsubishi Tanabe Pharma, though not primary HBIG producers, contribute through their broader infectious disease portfolios. Sangamo Therapeutics represents the future, focusing on gene editing technologies potentially offering novel therapeutic approaches beyond immunoglobulin for Hepatitis B. Strategic initiatives include expanding plasma collection networks, improving manufacturing efficiency, and exploring new indications for immunoglobulin therapies, driven by the persistent global prevalence of Hepatitis B and the need for effective prophylactic and treatment options.
List of Key Companies:
- LFB
- Takeda
- AbbVie
- Kedrion
- Sangamo Therapeutics
- Biotest
- Hemocue
- Mitsubishi Tanabe Pharma
- Octapharma
- CSL Behring
- Blood Products Laboratory
- Baxter
- Shire
- Emergent BioSolutions
- Grifols
- Genentech
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 2.8 Billion |
| Forecast Value (2035) | USD 5.1 Billion |
| CAGR (2026-2035) | 6.4% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
List of Tables
Table 1: Global Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2020-2035
Table 2: Global Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 3: Global Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 4: Global Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 5: Global Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 6: North America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2020-2035
Table 7: North America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 8: North America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 9: North America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 10: North America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 11: Europe Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2020-2035
Table 12: Europe Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 13: Europe Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 14: Europe Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 15: Europe Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Asia Pacific Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2020-2035
Table 17: Asia Pacific Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 18: Asia Pacific Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 19: Asia Pacific Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 20: Asia Pacific Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 21: Latin America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2020-2035
Table 22: Latin America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 23: Latin America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 24: Latin America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 25: Latin America Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 26: Middle East & Africa Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2020-2035
Table 27: Middle East & Africa Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 28: Middle East & Africa Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 29: Middle East & Africa Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 30: Middle East & Africa Hepatitis B Human Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035